Positive cooperativity between BAG956 and kinase inhibitors against BCR-ABL–expressing cells and mutant FLT3-expressing cells. Investigation of the effects of BAG956 in combination with imatinib (A), nilotinib (B), and rapamycin (C), respectively, on the proliferation of Ba/F3.p210 cells after approximately 3 days of treatment. (D) Investigation of the effects of BAG956 in combination with PKC412 on the proliferation of Ba/F3-FLT3-ITD cells after approximately 3 days of treatment. Concentrations of BAG956 used: 0, 0.0275 (25% IC₅₀), 0.055 (50% IC₅₀), 0.11 (100% IC₅₀), 0.22 (200% IC₅₀), 0.44 (400% IC₅₀) μM. Concentrations of imatinib used: 0, 0.075 (25% IC₅₀), 0.15 (50% IC₅₀), 0.3 (100% IC₅₀), 0.6 (200% IC₅₀), 1.2 μM (400% IC₅₀). Concentrations of nilotinib used: 0, 0.00 125 (25% IC₅₀), 0.0025 (50% IC₅₀), 0.005 (100% IC₅₀), 0.01 (200% IC₅₀), 0.02 (400% IC₅₀) μM. Concentrations of rapamycin used: 0, 0.00 025 (25% IC₅₀), 0.0005 (50% IC₅₀), 0.001 (100% IC₅₀), 0.002 (200% IC₅₀), 0.004 (400% IC₅₀) μM. Concentrations of PKC412 used: 0, 0.00 125 (25% IC₅₀), 0.0025 (50% IC₅₀), 0.005 (100% IC50), 0.01 (200% IC₅₀), 0.02 μM (400% IC₅₀).